Country: Israel
Language: Hebrew
Source: Ministry of Health
CEFALEXIN AS SODIUM
COMEX LTD
J01DB01
תרחיף להזרקה
CEFALEXIN AS SODIUM 180 MG/ML
תוך-שרירי, תת-עורי
מרשם נדרש
NORBROOK LABORATORIES LTD, NORTHEN IRELAND, UK
CEFALEXIN
2014-07-31
SIDE 1/2 PLEASE READ THIS IMPORTANT INFORMATION: Please ensure this proof matches your artwork requirements. Please check all aspects of the proof i.e. text, fonts, spelling, colours, size, construction, copy position, barcodes, pharma codes, orientation of graphics etc. Mark clearly any amendments which you identify. Receiving the signed approval of this proof will authorise Norbrook Laboratories to proceed with your order. Norbrook Laboratories will not be liable for the costs of an order produced where any amendments required were not identified on the signed proof. Please return the signed approval at your earliest convenience to enable us to proceed with the order and meet your requested delivery date. CUSTOMER...................... Comex COUNTRY......................... Jerusalem PRODUCT ......................... Solvasol Injection VOLUME ......................... Insert RESOURCE CODE............. (405)008472 REVISION LEVEL.............. I07 PHARMA CODE................ 622 BARCODE......................... n/a DIMENSIONS .................. 148 x 210mm KEYLINE (DIE) REF. ......... A5, Double-sided CLIENT ARTWORK APPROVAL - PROOF 1 - NORBROOK DESIGNER: EAMON MCALLISTER (2/9/2015) CUSTOMER APPROVAL (PLEASE SIGN) SIGNATURE: PRINT NAME: DATE: Artwork Department Station Works, Newry, Co. Down, BT35 6JP Tel: +44 ( 0 ) 28 3026 4435 E-mail: eamon.mcallister@norbrook.co.uk COLOURS USED: PMS Black PMS 072 Cefalexin (as sodium salt) 180 mg/ml . : . : : . . . : 10 " / " 5 . " 0.5 – 0.25 9.0 – 5.0 " : 1.5 – 0.5 27.9 – 9.0 " 3.0 – 1.5 54.0 – 27.0 " . . . : 7 " / " 5 . 1 / " 25 . " . 20 . " 20 . " : . . . . . . . , . : . . : – 6 , – . - SIDE 2/2 008472I07 : , , . cross reaction . . . . , . , , , . 25°C . . . . . 28 . , Apparent growth , . . : Caprylic Caprate Triglyceride : 082 97 92318 00 : : " – " 2014 . Read the complete document